Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Brain Injury-Pipeline Review, H2 2015

Brain Injury-Pipeline Review, H2 2015


  Request for Sample Report

Executive Summary

Brain Injury-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Brain Injury-Pipeline Review, H2 2015', provides an overview of the Brain Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Brain Injury

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Brain Injury and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Brain Injury

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Brain Injury Overview 6

Therapeutics Development 7

Pipeline Products for Brain Injury-Overview 7

Pipeline Products for Brain Injury-Comparative Analysis 8

Brain Injury-Therapeutics under Development by Companies 9

Brain Injury-Therapeutics under Investigation by Universities/Institutes 10

Brain Injury-Pipeline Products Glance 11

Early Stage Products 11

Brain Injury-Products under Development by Companies 12

Brain Injury-Products under Investigation by Universities/Institutes 13

Brain Injury-Companies Involved in Therapeutics Development 14

Acorda Therapeutics, Inc. 14

Biogen, Inc. 15

Chiesi Farmaceutici SpA 16

Faron Pharmaceuticals Oy 17

FibroGen, Inc. 18

Virogenomics, Inc. 19

Brain Injury-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 26

Drug Profiles 27

Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

FG-4497-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

interferon beta-1a-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Peptide to Inhibit Pannexin-1 for Brain Injury-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

PRE-084-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

RTL-551-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Block TRPC3 for Acute Brain Injury-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Brain Injury-Recent Pipeline Updates 42

Brain Injury-Dormant Projects 44

Brain Injury-Discontinued Products 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

Number of Products under Development for Brain Injury, H2 2015 7

Number of Products under Development for Brain Injury-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Products under Investigation by Universities/Institutes, H2 2015 13

Brain Injury-Pipeline by Acorda Therapeutics, Inc., H2 2015 14

Brain Injury-Pipeline by Biogen, Inc., H2 2015 15

Brain Injury-Pipeline by Chiesi Farmaceutici SpA, H2 2015 16

Brain Injury-Pipeline by Faron Pharmaceuticals Oy, H2 2015 17

Brain Injury-Pipeline by FibroGen, Inc., H2 2015 18

Brain Injury-Pipeline by Virogenomics, Inc., H2 2015 19

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Mechanism of Action, H2 2015 24

Number of Products by Stage and Route of Administration, H2 2015 25

Number of Products by Stage and Molecule Type, H2 2015 26

Brain Injury Therapeutics-Recent Pipeline Updates, H2 2015 42

Brain Injury-Dormant Projects, H2 2015 44

Brain Injury-Discontinued Products, H2 2015 45

List of Figures

Number of Products under Development for Brain Injury, H2 2015 7

Number of Products under Development for Brain Injury-Comparative Analysis, H2 2015 8

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 11

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Top 10 Targets, H2 2015 21

Number of Products by Stage and Top 10 Targets, H2 2015 21

Number of Products by Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Top 10 Molecule Types, H2 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Biogen, Inc.

Chiesi Farmaceutici SpA

Faron Pharmaceuticals Oy

FibroGen, Inc.

Virogenomics, Inc.

Brain Injury Therapeutic Products under Development, Key Players in Brain Injury Therapeutics, Brain Injury Pipeline Overview, Brain Injury Pipeline, Brain Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com